UNLABELLED: Pathologic fractures are often excluded in epidemiologic studies of osteoporosis. Using Medicare administrative data, we identified persons with vertebral and hip fractures. Among these, 48% (vertebral) and 3% (hip) of the fractures were coded as pathologic. Only 25% and 66% of persons with these pathologic fractures had evidence for malignancy. INTRODUCTION: Analyses of osteoporosis-related fractures that use administrative data often exclude pathologic fractures (ICD-9 733.1x) due to concern that these are caused by cancer. We examined "pathologic" fractures of the vertebrae and hip to evaluate their contribution to fracture incidence and assessed the evidence for a malignancy. METHODS: We studied US Medicare beneficiaries age > or =65 with new fractures identified using ICD-9 diagnosis codes 733.13 (pathologic vert), 805.0, 805.2, 805.4, 805.8 (nonpathologic vert); and 733.14 (pathologic hip), 820.0, 820.2, 820.8 (nonpathologic hip). We further examined the proportion of cases with a diagnosis of a malignancy proximate to the fracture. RESULTS: We identified 44,120 individuals with a vertebral fracture and 60,354 with a hip fracture. Approximately 48% of vertebral fractures and 3% of hip fractures were coded as pathologic. For only approximately 25% of persons with a "pathologic" vertebral fracture ICD-9 code, but 66% of persons with a "pathologic" hip fracture, there was evidence of a possible cancer diagnosis. CONCLUSION: Among US Medicare beneficiaries, one fourth of pathologic vertebral fracture and two thirds of pathologic hip fracture cases had evidence for a malignancy. Particularly for vertebral fractures, excluding persons with pathologic fractures in epidemiologic analyses that utilize administrative claims data substantially underestimates the burden of fractures due to osteoporosis.
UNLABELLED: Pathologic fractures are often excluded in epidemiologic studies of osteoporosis. Using Medicare administrative data, we identified persons with vertebral and hip fractures. Among these, 48% (vertebral) and 3% (hip) of the fractures were coded as pathologic. Only 25% and 66% of persons with these pathologic fractures had evidence for malignancy. INTRODUCTION: Analyses of osteoporosis-related fractures that use administrative data often exclude pathologic fractures (ICD-9 733.1x) due to concern that these are caused by cancer. We examined "pathologic" fractures of the vertebrae and hip to evaluate their contribution to fracture incidence and assessed the evidence for a malignancy. METHODS: We studied US Medicare beneficiaries age > or =65 with new fractures identified using ICD-9 diagnosis codes 733.13 (pathologic vert), 805.0, 805.2, 805.4, 805.8 (nonpathologic vert); and 733.14 (pathologic hip), 820.0, 820.2, 820.8 (nonpathologic hip). We further examined the proportion of cases with a diagnosis of a malignancy proximate to the fracture. RESULTS: We identified 44,120 individuals with a vertebral fracture and 60,354 with a hip fracture. Approximately 48% of vertebral fractures and 3% of hip fractures were coded as pathologic. For only approximately 25% of persons with a "pathologic" vertebral fracture ICD-9 code, but 66% of persons with a "pathologic" hip fracture, there was evidence of a possible cancer diagnosis. CONCLUSION: Among US Medicare beneficiaries, one fourth of pathologic vertebral fracture and two thirds of pathologic hip fracture cases had evidence for a malignancy. Particularly for vertebral fractures, excluding persons with pathologic fractures in epidemiologic analyses that utilize administrative claims data substantially underestimates the burden of fractures due to osteoporosis.
Authors: Russel Burge; Bess Dawson-Hughes; Daniel H Solomon; John B Wong; Alison King; Anna Tosteson Journal: J Bone Miner Res Date: 2007-03 Impact factor: 6.741
Authors: Jeffrey R Curtis; Amy S Mudano; Daniel H Solomon; Juan Xi; Mary Elkins Melton; Kenneth G Saag Journal: Med Care Date: 2009-01 Impact factor: 2.983
Authors: Amanda R Patrick; M Alan Brookhart; Elena Losina; John T Schousboe; Suzanne M Cadarette; Helen Mogun; Daniel H Solomon Journal: J Clin Endocrinol Metab Date: 2010-05-05 Impact factor: 5.958
Authors: L Bessette; S Jean; M-P Lapointe-Garant; E L Belzile; K S Davison; L G Ste-Marie; J P Brown Journal: Osteoporos Int Date: 2011-09-17 Impact factor: 4.507
Authors: F Lapi; F Cipriani; A P Caputi; G Corrao; A Vaccheri; M C Sturkenboom; M Di Bari; D Gregori; F Carle; T Staniscia; A Vestri; M Brandi; V Fusco; G Campisi; G Mazzaglia Journal: Osteoporos Int Date: 2012-05-23 Impact factor: 4.507
Authors: Afsaneh Barzi; Dawn L Hershman; Cathee Till; William E Barlow; Scott Ramsey; Heinz-Josef Lenz; Howard S Hochster; Joseph M Unger Journal: Arch Osteoporos Date: 2019-07-28 Impact factor: 2.617
Authors: Shreyasee Amin; Sara J Achenbach; Elizabeth J Atkinson; Sundeep Khosla; L Joseph Melton Journal: J Bone Miner Res Date: 2014-03 Impact factor: 6.741
Authors: Charles E Leonard; Colleen M Brensinger; Thanh Phuong Pham Nguyen; John R Horn; Sophie Chung; Warren B Bilker; Sascha Dublin; Samantha E Soprano; Ghadeer K Dawwas; David W Oslin; Douglas J Wiebe; Sean Hennessy Journal: Biomed Pharmacother Date: 2020-07-30 Impact factor: 6.529
Authors: William Palmer; Laura Bancroft; Fiona Bonar; Jung-Ah Choi; Anne Cotten; James F Griffith; Philip Robinson; Christian W A Pfirrmann Journal: Skeletal Radiol Date: 2020-06-02 Impact factor: 2.199